PITTSBURGH, April 15 /PRNewswire/ -- Precision Therapeutics will present two abstracts at the upcoming American Association for Cancer Research (AACR) meeting to be held in Washington, D.C. April 17-21.    

Using 27 different breast cancer cell lines, the abstract titled, "Identification of Multi-Drug Response Genes by Meta-Analysis based on ChemoFx® in Human Breast Cancer Cell Lines," identified genes which are associated with response to different drugs, and genes associated with ChemoFx®-determined responsiveness.  

The abstract titled, "Analysis of Biological Pathways Associated with Epirubicin and/or Cyclophosphamide Response by Pathway Enrichment Analysis in Human Breast Cancers," used ChemoFx® to determine responsiveness to two specific chemotherapy agents or the combination of these agents.  Publicly available microarray data for these cell lines were compared with ChemoFx® results, and pathway enrichment analysis was employed to detect specific biochemical pathways associated with these drug responses.

Results described in both abstracts/posters indicate the potential utility of ChemoFx® and gene expression analysis in predicting individual patient response to chemotherapy.

"We are very pleased and honored to be presenting these two abstracts at the AACR meeting. Having this research accepted for publication is a tremendous milestone for cancer patients as well as for the advancement of genomic research in personalized medicine," said Sean McDonald, CEO of Precision Therapeutics.  

About Precision Therapeutics

Precision Therapeutics, a life sciences company and leader in the development of innovative technology, delivers personalized diagnostics to physicians with the goal of supporting and optimizing difficult treatment decisions for patients with cancer.  Precision's ChemoFx®, a proprietary drug response marker, measures an individual patients' tumor response to a range of therapeutic alternatives under consideration by a physician.  For more information, please visit www.precisiontherapeutics.com, or www.chemofx.com.

SOURCE Precision Therapeutics, Inc.

Back to top

RELATED LINKS
http://www.precisiontherapeutics.com